Selank

A synthetic heptapeptide anxiolytic derived from the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with the same Pro-Gly-Pro stabilizing extension used in Semax. Developed alongside Semax at the Institute of Molecular Genetics in Russia, Selank is approved there as an anxiolytic and nootropic with immunomodulatory properties.

• Modulates GABAergic neurotransmission, enhancing inhibitory signaling without direct GABA-A receptor binding
• Influences expression of BDNF and serotonin transporter genes
• Tuftsin backbone activates phagocytic immune cells and modulates cytokine expression
• Stabilizes enkephalin degradation, indirectly enhancing endogenous opioid tone

• Pregnancy or breastfeeding
• Active autoimmune conditions (due to immunomodulatory effects)
• Known hypersensitivity to tuftsin-derived compounds

Store at 2–8°C (36–46°F) for up to 6 months. Reconstituted nasal solutions: refrigerate and use within 30 days. Avoid repeated freeze-thaw cycles.

Commonly supplied as a 0.15% intranasal solution. If lyophilized, reconstitute with bacteriostatic water.

Selank was approved in Russia in 2009 for generalized anxiety disorder and as a nootropic. Clinical studies demonstrated anxiolytic efficacy comparable to medazepam (a benzodiazepine) without sedation, cognitive impairment, or withdrawal symptoms. Research has confirmed its influence on over 50 genes related to GABAergic signaling, serotonin transport, and immune function. Its dual anxiolytic-immunomodulatory profile is unique among peptide-based compounds.